International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

• Authors: DISPENZIERI A.; KYLE R.; MERLINI G.; MIGUEL JS.; LUDWIG H.; HÁJEK Roman; PALUMBO A.; JAGANNATH S.; BLADE J.; LONIAL S.; DIMOPOULOS M.; COMENZO R.; EINSELE H.; BARLOGIE B.; ANDERSON K.; GERTZ M.; HAROUSSEAU JL.; ATTAL M.; TOSI P.; SONNEVELD P.; BOCCADORO M.; MORGAN G.; RICHARDSON P.; SEZER O.; MATEOS MV.; CAVO M.; JOSHUA D.; TURESSON I.; CHEN W.; SHIMIZU K.; POWLES R.; RAJKUMAR SV.; DURIE BG.
• Year of publication: 2009
• Type: Article in Periodical
• Magazine / Source: Leukemia
• MU Faculty or unit: Faculty of Medicine
• Field: Oncology and hematology
• Keywords: multiple myeloma; free light chain;guidelines
• Description: The serum immunoglobulin-free light chain (FLC) assay measures levels of free kappa and lambda immunoglobulin light chains. There are three major indications for the FLC assay in the evaluation and management of multiple myeloma and related plasma cell disorders (PCD). This paper provides consensus guidelines for the use of this important assay, in the diagnosis and management of clonal PCD.